Search research articles
Contact Us
Filters
Showing results (41-50 of 105) with videos related to
Page
of 11
Sort By:
Archives of Biochemistry and Biophysics
|
October 29, 1997
Interaction of fibroblast growth factor-1 and related peptides with heparan sulfate and its oligosaccharides
J R Fromm, R E Hileman, J M Weiler, et al.
Cytometry. Part B, Clinical Cytometry
|
October 24, 2018
Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma
Ravnit-Kaur Grewal, Manogari Chetty, Emmanuel-Akinola Abayomi, et al.
British Journal of Haematology
|
June 20, 2025
Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies
Afshin Shameli, Tori Catey, Valerie Woodings, et al.
Cancer Biology & Therapy
|
February 16, 2024
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
Hongjie Wang, Theo Koob, Jonathan R Fromm, et al.
American Journal of Clinical Pathology
|
June 27, 2021
De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine Learning
Paul D Simonson, Yue Wu, David Wu, et al.
Clinical Neuropathology
|
October 11, 2017
The first report of human primary thoracic spine mast cell sarcoma: a case report
Ali C Ravanpay, Jonathan R Fromm, Kerstin L Edlefsen, et al.
Cytometry. Part B, Clinical Cytometry
|
August 6, 2014
Apparent CD19 expression by natural killer cells: a potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia
Lorinda Soma, David Wu, Xueyan Chen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 19, 2014
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
Stephen J Salipante, Jonathan R Fromm, Jay Shendure, et al.
Cytometry. Part B, Clinical Cytometry
|
July 22, 2014
Apparent CD19 expression by natural killer cells: A potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia
Lorinda Soma, David Wu, Xueyan Chen, et al.
Cytometry. Part B, Clinical Cytometry
|
September 7, 2016
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy
Sindhu Cherian, Valerie Miller, Vivian McCullouch, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 105) with videos related to
Sort By:
Page
of 11
Archives of Biochemistry and Biophysics
|
October 29, 1997
Interaction of fibroblast growth factor-1 and related peptides with heparan sulfate and its oligosaccharides
J R Fromm, R E Hileman, J M Weiler, et al.
Cytometry. Part B, Clinical Cytometry
|
October 24, 2018
Use of flow cytometry in the phenotypic diagnosis of hodgkin's lymphoma
Ravnit-Kaur Grewal, Manogari Chetty, Emmanuel-Akinola Abayomi, et al.
British Journal of Haematology
|
June 20, 2025
Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies
Afshin Shameli, Tori Catey, Valerie Woodings, et al.
Cancer Biology & Therapy
|
February 16, 2024
CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
Hongjie Wang, Theo Koob, Jonathan R Fromm, et al.
American Journal of Clinical Pathology
|
June 27, 2021
De Novo Identification and Visualization of Important Cell Populations for Classic Hodgkin Lymphoma Using Flow Cytometry and Machine Learning
Paul D Simonson, Yue Wu, David Wu, et al.
Clinical Neuropathology
|
October 11, 2017
The first report of human primary thoracic spine mast cell sarcoma: a case report
Ali C Ravanpay, Jonathan R Fromm, Kerstin L Edlefsen, et al.
Cytometry. Part B, Clinical Cytometry
|
August 6, 2014
Apparent CD19 expression by natural killer cells: a potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia
Lorinda Soma, David Wu, Xueyan Chen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
April 19, 2014
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
Stephen J Salipante, Jonathan R Fromm, Jay Shendure, et al.
Cytometry. Part B, Clinical Cytometry
|
July 22, 2014
Apparent CD19 expression by natural killer cells: A potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia
Lorinda Soma, David Wu, Xueyan Chen, et al.
Cytometry. Part B, Clinical Cytometry
|
September 7, 2016
A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy
Sindhu Cherian, Valerie Miller, Vivian McCullouch, et al.
Page
of 11